Tobam Trims Position in Humana Inc. (NYSE:HUM)

Tobam cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 41.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,966 shares of the insurance provider's stock after selling 6,443 shares during the quarter. Tobam's holdings in Humana were worth $2,372,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after buying an additional 1,751,857 shares during the last quarter. Dodge & Cox raised its position in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC grew its stake in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the period. Geode Capital Management LLC grew its stake in shares of Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after purchasing an additional 63,562 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after purchasing an additional 550,692 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

HUM stock traded down $0.09 during midday trading on Friday, reaching $234.87. The stock had a trading volume of 1,512,489 shares, compared to its average volume of 1,794,248. The company's fifty day simple moving average is $250.43 and its 200 day simple moving average is $262.65. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a market cap of $28.35 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43. Humana Inc. has a 52-week low of $212.45 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the firm posted $7.23 EPS. As a group, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.51%. Humana's dividend payout ratio is presently 25.04%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Mizuho raised their price objective on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Truist Financial dropped their price objective on shares of Humana from $325.00 to $305.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Robert W. Baird raised their price objective on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $284.24.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.